




Precision-Characterized Human Biological Assets

Donor-linked cells, longitudinal metadata and fit-for-purpose selection for decision-relevant research.

The goal of this document is to support the efforts to partner for success, by aligning scientific, commercial and financial goals.

SCIENTIFIC & TECHNICAL INVESTOR PRESENTATION



Randomization Controls Selection; Characterization Controls Knowledge

RANDOMIZATION

Controls how subjects or samples are selected within a defined population.

BLINDNESS

Limits which biological covariates are available for design, stratification and interpretation.

Random selection and biological characterization can coexist.

Model Performance Is Conditional on the Biology Introduced

Unmeasured donor heterogeneity can become latent experimental variance—affecting assay response, effect-size estimation, reproducibility and the interpretation of concordant or discordant results.



BIOLOGICAL INPUTS BOUND MODEL INTERPRETABILITY

Blind, Random Sampling Can Obscure Biologically Relevant Structure

COMMONLY AVAILABLE METADATA

- Sex and age
- Basic health status
- Collection and processing records




POTENTIALLY UNOBSERVED COVARIATES

Immune state • biomarker profile • medication and treatment history • longitudinal change • phenotype-specific eligibility

Donor scarcity can further constrain cohort composition and increase reliance on available—not necessarily informative—samples.

FCBio Integrates Donor Phenotyping, Collection and Research Demand



A closed operating architecture links the donor, every collection, every derived product, every stored aliquot and every research requirement.

The SMART Integrated Profile™ Makes Biological Context Queryable

DONOR-LEVEL DATA


- Demographics and eligibility
- Health, medication and treatment history
- CellDecoder™ screening: 150+ biomarkers
- Repeat measurements and longitudinal metadata

ASSET-LEVEL DATA

- Collection time and specimen provenance
- Processing method and preanalytical variables
- Cell composition, QC and release criteria
- Available derivatives, aliquots and repository history

Observed data remain distinguishable from inferred classification and customer-defined relevance.

Characterization Defines the Sampling Frame Before Randomization



The investigator—not the supplier—determines which variables are scientifically relevant.

FCBio preserves optionality: blind/random commodity supply remains available when the design requires it.

Preamanalytical Provenance Is Part of the Biological Asset




- Donor eligibility and collection conditions
- Anticoagulant, timing and temperature
- Processing method and operator traceability
- Cell separation, QC and release attributes
- Cryopreservation, storage and retrieval history

Without traceable preanalytical context, technical variation can be misinterpreted as donor biology—or donor biology can be dismissed as technical noise.

Repeat Collections Convert Cross-Sectional Samples Into Longitudinal Assets



Baseline



Return




Later state

WITHIN-DONOR SIGNAL

Phenotypic drift
Treatment effects
Health-state
transitions
Biomarker trajectories
Matched derivatives
Repository continuity

Longitudinal metadata can help separate inter-donor heterogeneity from intra-donor biological change.

Repository Strategy Couples Inventory Decisions to Observed Research Demand



Commodity orders can replenish broad inventory; SMART orders can replenish phenotype-specific inventory.

Characterized Starting Material Supports Fit-for-Purpose NAM Implementation

FDA NAM VALIDATION PRINCIPLES

- Context of use
- Human biological relevance
- Technical characterization
- Fit-for-purpose performance

STARTING-MATERIAL CONTRIBUTION

- Defined donor populations and biological covariates
- Traceable collection and processing parameters
- Documented variability and QC attributes
- Retained context for mechanistic interpretation

FCBio supplies characterized biological inputs; NAM developers and end users establish model validity within a defined context of use.

FCBio Serves Both Conventional Supply and Precision-Characterized Demand

CONVENTIONAL BIOSPECIMENS

- Qualified human material
- Standard donor metadata
- Random selection when requested
- Broad research applicability
- Fresh or repository fulfillment

SMART SAMPLES


- Deeper donor phenotyping
- Context-specific cohorting
- CellDecoder™ biomarker screening
- Matching and harder-to-find criteria
- Longitudinal and repository linkage

The customer selects the level of biological knowledge required by the experimental context.

Revenue Is Layered Across Material, Information and Scientific Services



Whole blood, bone marrow and apheresis



Separated cells and derived products

COMMERCIAL COMPONENTS

Base biological material
SMART characterization
Matching / specificity premium
Special processing and QC
Repository storage and retrieval
Reserved inventory and delivery
Scientific collaboration

Material

Information

Matching

Processing

Storage

Delivery

Collaborate

Every order must be profitable without assuming complete utilization of each donor collection or eventual sale of stored inventory.

The Compounding Advantage Is the Connected Biological History—not the Algorithm

Donor phenotype

Repeat collections

Linked derivatives

Repository history

RFQs and orders

Observed fulfillment

AI-ASSISTED MATCHING • INVENTORY OPTIMIZATION • PATTERN RECOGNITION

Algorithms can be acquired. A governed, longitudinally connected dataset of real donors, real assets and real demand must be accumulated through operations.

The San Francisco Center Establishes the Operating and Scientific Model

WHY THE BAY AREA

- Concentrated biotechnology and pharmaceutical R&D
- Broad and diverse donor population
- Direct delivery of short-lived fresh products
- Existing industry relationships
- National and global reach through frozen inventory



Center 1 validates donor recruitment, laboratory throughput, repository management and demand-linked fulfillment before replication.

Commercial Signals Support Further Scientific and Operating Validation

130+

historical customers

\$650K+

historical distribution
sales

\$4.75M+

requests for quotations
(RFQ)

12

acquisition inquiries

Historical sales evidence operating experience. RFQs and acquisition inquiries indicate market interest, but do not constitute booked revenue or scientific validation.

Built by Scientific, Operational, Commercial and Financial Operators



Jan (Johannes) Breukers

Founder and CEO

35+ years in life-science supply, customer development, company building and business management consulting.



Sam Vasilevsky, PhD

Founder and COO

25+ years in life-science and biotechnology supply; sales, operations and scientific execution.



Kamran Tahamtanzadeh

Founder and Business Development Officer

30+ years in life sciences; company development, industry relationships and commercialization.



Jason Aulenbach

Founder and CFO

15+ years in accounting and financial management, including five years supporting life-science operations.

The funding round adds laboratory, donor recruitment, quality, data and commercial personnel for Center 1.

Advisory Board Extends Scientific, Technical and Commercial Depth



Michelle Cunningham

Life-Science Advisor

25+ years in life sciences;
industry specialist.



Baback Gharizadeh

Life-Science Advisor

20+ years in life sciences;
industry specialist.



David White

Business Strategy

35+ years advising small and
medium-sized businesses.



Tim Kapp

Automation & AI

25+ years in automation and
artificial intelligence.



Daya D. Verma

**Technical Product Leader /
CMC Lead**

20+ years across biologics,
cell and gene therapy, and
small-molecule CMC;
portfolio leadership,
business development,
licensing and M&A.

Five advisors broaden FCBio's perspective across life sciences, CMC, business strategy, automation, AI, licensing and M&A.

\$7.5 Million to Launch the First Integrated Collection Center

CAPITAL DEPLOYMENT

- Facility preparation and laboratory equipment
- Donor recruitment and reimbursement
- AI integration and global donor-to-demand matching
- Collection, laboratory and quality personnel
- Screening and donor-information systems
- Repository capacity
- Customer acquisition and fulfillment
- Operating runway through commercial ramp

INTENDED TECHNICAL AND COMMERCIAL RESULT

A replicable collection-center architecture that generates revenue while accumulating a governed, longitudinal history of donors, SMART Samples, repository assets and global research demand.

The capital builds the operating system that the data advantage requires.